Show simple item record

dc.contributor.authorStewart, Alan Len
dc.date.accessioned2010-04-08T10:38:27Z
dc.date.available2010-04-08T10:38:27Z
dc.date.issued1996-06
dc.identifier.citationOptimal control of cyclophosphamide-induced emesis. 1996, 53 Suppl 1:32-8 Oncologyen
dc.identifier.issn0030-2414
dc.identifier.pmid8692548
dc.identifier.urihttp://hdl.handle.net/10541/95981
dc.description.abstractCyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide (> or = 450 mg/m2). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous 'oral' (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.
dc.language.isoenen
dc.subject.meshAntiemetics
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCyclophosphamide
dc.subject.meshDoxorubicin
dc.subject.meshEpirubicin
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshLomustine
dc.subject.meshMethotrexate
dc.subject.meshProcarbazine
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshVomiting
dc.titleOptimal control of cyclophosphamide-induced emesis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalOncologyen
html.description.abstractCyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide (> or = 450 mg/m2). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous 'oral' (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.


This item appears in the following Collection(s)

Show simple item record